Angiotensin Peptides and SARS-CoV-2: Mechanistic Insights from Binding Studies

Study Background and Research Question

The renin-angiotensin system (RAS) is a central regulator of cardiovascular and renal physiology, with peptide hormones such as angiotensin II playing key roles in blood pressure regulation and fluid balance. In the context of the COVID-19 pandemic, the interface between RAS components and the SARS-CoV-2 viral entry process has attracted considerable attention. The SARS-CoV-2 virus uses its spike protein to engage host cell receptors, most notably angiotensin-converting enzyme 2 (ACE2), but recent evidence has identified AXL and neuropilin-1 (NRP1) as additional receptors facilitating viral entry, particularly in tissues with low ACE2 expression (source: Oliveira et al., 2025).

The reference study by Oliveira et al. (2025) addresses a critical question: Do naturally occurring angiotensin peptides modulate the binding affinity of the SARS-CoV-2 spike protein to its host receptors, and if so, through what structural determinants?

Key Innovation from the Reference Study

This work is the first to systematically compare the effects of various angiotensin peptide truncations, including the H2N-Ile-His-Pro-OH peptide (Angiotensin 1/2 (5-7)), on the enhancement of SARS-CoV-2 spike protein binding to the AXL receptor. Notably, the study uncovers that not only full-length angiotensin II, but also its C- and N-terminally truncated derivatives, can significantly increase spike–AXL binding—an effect not observed for ACE2 or NRP1 with most truncations (source: Oliveira et al., 2025).

Among the truncated forms, those lacking N-terminal residues (e.g., angiotensin (2–8), angiotensin IV (3–8), and shorter fragments such as angiotensin (5–7)) exhibit even greater potency, delivering a 2.7-fold increase in spike–AXL binding in the case of angiotensin IV. The study further demonstrates that specific modifications at position 4 (such as tyrosine phosphorylation or substitution by valine) in angiotensin II amplify the enhancement effect, suggesting a structural basis for receptor interaction specificity.

Methods and Experimental Design Insights

Oliveira et al. employed antibody-based binding assays to quantify the interaction between SARS-CoV-2 spike protein and three host receptors (AXL, ACE2, NRP1) in the presence of various angiotensin peptides. The comparative analysis included full-length angiotensin I (1–10), angiotensin II (1–8), and their systematically truncated derivatives. The experimental design allowed for the dissection of both sequence length and amino acid modifications on binding outcomes.

Key controls included measurements with untreated spike proteins and assessments across multiple receptors to isolate AXL-specific effects. The study also investigated the impact of chemical modifications at the peptide's tyrosine residue, focusing on how these alterations influenced spike–receptor binding.

Core Findings and Why They Matter

Several significant conclusions arise from this study:

• AXL-Specific Enhancement: Angiotensin II increases spike–AXL binding by two-fold, an effect that is preserved or amplified in shorter peptides such as angiotensin (1–7), (1–6), and more potently in N-terminally truncated forms like angiotensin (5–7) (source: Oliveira et al., 2025).
• Sequence-Dependent Activity: While C-terminal deletions maintain or slightly reduce activity, N-terminal deletions generate peptides with greater binding enhancement.
• Role of Tyrosine Modifications: Substitution or phosphorylation of tyrosine at position 4 further increases spike–AXL binding, indicating the importance of side-chain chemistry for receptor interaction.
• Limited ACE2/NRP1 Effects: Most angiotensin peptides do not enhance spike binding to ACE2 or NRP1, except for angiotensin IV, which also impacts these receptors.

These findings suggest that circulating angiotensin fragments, such as Angiotensin 1/2 (5-7), may modulate SARS-CoV-2 cellular entry in tissues expressing AXL, potentially influencing viral tropism and severity in individuals with altered RAS activity (source: Oliveira et al., 2025).

Comparison with Existing Internal Articles

Internal resources have previously explored the mechanistic roles of Angiotensin 1/2 (5-7) in blood pressure regulation and RAS signaling (see Mechanistic Insights), and its application as a vasoconstrictor peptide hormone in hypertension models (Precision Vasoconstrictor). However, the reference study uniquely connects these classic cardiovascular functions to viral pathogenesis via spike–AXL binding modulation.

Further, the internal article "Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding" provides a translational overview of these mechanistic findings, confirming the centrality of truncated angiotensin peptides in cross-domain research on cardiovascular-viral interfaces. This cross-referencing allows researchers to contextualize the new evidence from Oliveira et al. within a broader landscape of cardiovascular and infectious disease research frameworks.

Protocol Parameters

• binding assay | 2-fold increase in spike–AXL binding with angiotensin II | viral entry studies | demonstrates direct modulation of viral–host interaction by RAS peptides | paper
• binding assay | up to 2.7-fold increase with angiotensin IV | receptor specificity mapping | identifies sequence determinants for enhanced viral binding | paper
• peptide concentration | not explicitly reported (recommend titration 0.1–10 μM) | in vitro binding assays | standard for peptide–protein interaction studies | workflow_recommendation
• chemical modification | tyrosine phosphorylation/substitution increases effect | structure–activity relationship analysis | reveals modifiable determinants for peptide engineering | paper

Limitations and Transferability

The study's antibody-based binding assays provide robust quantitative comparisons but do not address downstream cellular infection or in vivo pathogenesis. The precise concentrations of angiotensin peptides in physiological or pathophysiological states remain to be correlated with the observed in vitro enhancement effects. Additionally, while AXL is established as a viral entry receptor in some cell types, the broader relevance of these findings across diverse human tissues and disease states requires further validation (source: Oliveira et al., 2025).

Transferability to clinical settings will depend on future studies linking angiotensin peptide levels, AXL expression, and actual infection outcomes in patient cohorts. It is also important to note that the study does not report functional viral infection assays, so the implications for disease progression are inferred rather than directly tested.

Why this cross-domain matters, maturity, and limitations

The interface between RAS-derived peptides and viral receptor engagement highlights a mechanistic bridge between cardiovascular and infectious disease research. This cross-domain insight is particularly relevant given the recognized impact of hypertension and RAS dysregulation on COVID-19 outcomes. However, the maturity of this field is early-stage; while the molecular mechanism of spike–AXL binding enhancement is well-supported in vitro, translation to in vivo or clinical contexts remains to be established. Limitations include the lack of direct infectivity data and the need for peptide concentration benchmarking in biological samples (source: Oliveira et al., 2025).

Research Support Resources

Researchers aiming to replicate or expand on these findings can utilize well-characterized angiotensin peptides for in vitro and in vivo studies. For example, Angiotensin 1/2 (5-7) (SKU A1049) from APExBIO offers a highly pure H2N-Ile-His-Pro-OH peptide suitable for receptor binding and signaling assays. Its validated solubility and stability parameters facilitate use in diverse biochemical workflows studying the renin-angiotensin system, blood pressure regulation, or spike protein interactions (source: product_spec). When designing experiments, consult recent mechanistic literature to optimize peptide concentrations and analytic endpoints.